<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Can Fite Biopharma Ltd — News on 6ix</title>
    <link>https://6ix.com/company/can-fite-biopharma-ltd</link>
    <description>Latest news and press releases for Can Fite Biopharma Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Apr 2026 12:31:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/can-fite-biopharma-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683626ed78dffbe2df143cfe.webp</url>
      <title>Can Fite Biopharma Ltd</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd</link>
    </image>
    <item>
      <title>Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-reports-positive-phase-2a-data-with-namodenoson-in-pancreatic-cancer-35percent-of-patients-remain-on-therapy-including-one-beyond-16-months</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-reports-positive-phase-2a-data-with-namodenoson-in-pancreatic-cancer-35percent-of-patients-remain-on-therapy-including-one-beyond-16-months</guid>
      <pubDate>Thu, 30 Apr 2026 12:31:00 GMT</pubDate>
      <description>Ramat Gan, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. The data from the fully enrolled study demonstrate preliminary evidence of clinical activity, including durable</description>
    </item>
    <item>
      <title>Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fites-partner-vetbiolix-completes-enrollment-in-phase-2-osteoarthritis-study-in-dogs-treated-with-piclidenoson-data-expected-in-q3-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fites-partner-vetbiolix-completes-enrollment-in-phase-2-osteoarthritis-study-in-dogs-treated-with-piclidenoson-data-expected-in-q3-2026</guid>
      <pubDate>Mon, 30 Mar 2026 11:20:00 GMT</pubDate>
      <description>Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 study of Piclidenoson for the treatment of osteoarthritis in dogs. Vetbiolix, Can-</description>
    </item>
    <item>
      <title>Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-reports-2025-financial-results-and-ongoing-clinical-progress-highlighting-positive-data-in-phase-2a-pancreatic-cancer-and-9-years-cancer-free-survival-in-liver-cancer-patient</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-reports-2025-financial-results-and-ongoing-clinical-progress-highlighting-positive-data-in-phase-2a-pancreatic-cancer-and-9-years-cancer-free-survival-in-liver-cancer-patient</guid>
      <pubDate>Thu, 26 Mar 2026 13:27:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study in pancreatic cancer met its primary endpoint of safety in heavily pretreated patien</description>
    </item>
    <item>
      <title>Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-expands-namodenoson-anti-obesity-franchise-with-israeli-patent-allowance</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-expands-namodenoson-anti-obesity-franchise-with-israeli-patent-allowance</guid>
      <pubDate>Tue, 17 Mar 2026 11:47:00 GMT</pubDate>
      <description>Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Israeli Patent Office has allowed its patent application No. 284463, titled “An A3 Adenosine Receptor Liga</description>
    </item>
    <item>
      <title>Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-announces-exercise-of-warrants-for-approximately-dollar40-million-in-gross-proceeds</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-announces-exercise-of-warrants-for-approximately-dollar40-million-in-gross-proceeds</guid>
      <pubDate>Wed, 04 Mar 2026 15:25:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 795,869 American Depositary Shares (ADSs), having an exercise price of $9.34 pe</description>
    </item>
    <item>
      <title>Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-announces-scientific-breakthrough-publication-demonstrating-anti-obesity-effect-of-namodenoson</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/can-fite-announces-scientific-breakthrough-publication-demonstrating-anti-obesity-effect-of-namodenoson</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
      <description>Namodenoson’s Favorable Safety Profile and Broad Patent Portfolio Positions it as a Promising Candidate in the Growing Obesity Treatment Market Ramat Gan, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company advancing a pipeline of proprietary small molecule drugs addressing oncological and inflammatory diseases, today announced the publication of a peer-reviewed study in the International Journal of Obesity</description>
    </item>
    <item>
      <title>Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-receives-canadian-patent-allowance-120000555</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-receives-canadian-patent-allowance-120000555</guid>
      <pubDate>Mon, 09 Feb 2026 12:00:00 GMT</pubDate>
      <description>Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application</description>
    </item>
    <item>
      <title>Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-patient-decompensated-liver-cirrhosis-120000236</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-patient-decompensated-liver-cirrhosis-120000236</guid>
      <pubDate>Thu, 05 Feb 2026 12:00:00 GMT</pubDate>
      <description>Namodenoson Provided Clinical Stabilization as a Potential Bridge to Transplant in Advanced Liver Failure Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that a patient with advanced decompensated liver cirrhosis who was treated with Namodenoson subsequently underwent a successful liver</description>
    </item>
    <item>
      <title>Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-completes-patient-enrollment-phase-120000949</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-completes-patient-enrollment-phase-120000949</guid>
      <pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
      <description>Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026 Ramat Gan, Israel, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that patient enrollment has been completed in its Phase 2a pancreatic cancer clinical trial of Namodenoson. The Phase 2a study is</description>
    </item>
    <item>
      <title>Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-granted-brazilian-patent-treatment-120000333</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-granted-brazilian-patent-treatment-120000333</guid>
      <pubDate>Fri, 26 Dec 2025 12:00:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced that the Brazilian Patent Office (INPI) has granted Patent No. BR112015002697-4, entitled “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.” The granted patent provides intellectual-property protection in Braz</description>
    </item>
    <item>
      <title>Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-announces-reverse-split-ordinary-214600798</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-announces-reverse-split-ordinary-214600798</guid>
      <pubDate>Tue, 23 Dec 2025 21:46:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced today that following the approval of its shareholders on November 10, 2025, its Board of Directors has approved a 1-for-3,000 reverse split of the Company’s ordinary shares. The reverse split will be recorded with the Tel-Aviv Stock Exchange on Ja</description>
    </item>
    <item>
      <title>Can-Fite Provides Update on Clinical and Financial Status</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-provides-clinical-financial-status-141900611</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-provides-clinical-financial-status-141900611</guid>
      <pubDate>Tue, 16 Dec 2025 14:19:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced an update on its clinical development activities and financial status. Namodenoson drug candidate: Can-Fite is currently enrolling patients in a pivotal Phase III clinical study evaluating Namodenoson for the treatment of advanced hepatocell</description>
    </item>
    <item>
      <title>Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-latest-developments-advanced-stage-120000173</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-latest-developments-advanced-stage-120000173</guid>
      <pubDate>Wed, 26 Nov 2025 12:00:00 GMT</pubDate>
      <description>RAMAT GAN, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that its CEO, Motti Farbstein will present at NobleCon21—Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference—at Florida Atlantic University, Executive Education Complex, in Boca Raton, Floria—on Wednesday, December 3</description>
    </item>
    <item>
      <title>Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-advance-veterinary-partnership-opportunities-120000184</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-advance-veterinary-partnership-opportunities-120000184</guid>
      <pubDate>Mon, 24 Nov 2025 12:00:00 GMT</pubDate>
      <description>Namodenoson, a Phase III cancer drug has strong potential in veterinary oncology, a market projected to reach $3.1 billion by 2030 Piclidenoson is currently in development for the treatment of osteoarthritis in pets; Clinical studies show efficacy in dogs, representing a $3 billion market RAMAT GAN, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncolo</description>
    </item>
    <item>
      <title>Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-cf602-erectile-dysfunction-treatment-120000230</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-cf602-erectile-dysfunction-treatment-120000230</guid>
      <pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
      <description>~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these drugs can be contraindicated for an estimated 16 million men living with diabetes CF602’s unique mechanism of action enables potential treatment of diabetic patients RAMAT GAN, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting</description>
    </item>
    <item>
      <title>Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-9-survival-complete-cure-120000273</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-9-survival-complete-cure-120000273</guid>
      <pubDate>Tue, 18 Nov 2025 12:00:00 GMT</pubDate>
      <description>Pivotal Phase III liver cancer study enrolling in Europe and Israel RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, announced today that a patient treated with Namodenoson has reached an overall survival of 9 years to date with complete response to treatment. The patient, who suffered from advanced liver</description>
    </item>
    <item>
      <title>Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-reports-complete-resolution-esophageal-110000820</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-reports-complete-resolution-esophageal-110000820</guid>
      <pubDate>Mon, 15 Sep 2025 11:00:00 GMT</pubDate>
      <description>Ramat Gan, Israel, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced a significant new clinical finding under its compassionate use program in decompensated liver cirrhosis. The patient, previously reported by Can-Fite to have experienced the disappearance of end-stage liver disease complications while rece</description>
    </item>
    <item>
      <title>Can-Fite Reports H1 2025 Financial Results and Clinical Update</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-reports-h1-2025-financial-124700966</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-reports-h1-2025-financial-124700966</guid>
      <pubDate>Thu, 28 Aug 2025 12:47:00 GMT</pubDate>
      <description>Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical &amp; Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone The Phase 2a st</description>
    </item>
    <item>
      <title>Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/pancreatic-cancer-phase-2a-study-110400111</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/pancreatic-cancer-phase-2a-study-110400111</guid>
      <pubDate>Wed, 30 Jul 2025 11:04:00 GMT</pubDate>
      <description>Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase 2a stu</description>
    </item>
    <item>
      <title>Can-Fite Announces Up To $15.0 Million Public Offering</title>
      <link>https://6ix.com/company/can-fite-biopharma-ltd/news/fite-announces-15-0-million-162400697</link>
      <guid isPermaLink="true">https://6ix.com/company/can-fite-biopharma-ltd/news/fite-announces-15-0-million-162400697</guid>
      <pubDate>Mon, 28 Jul 2025 16:24:00 GMT</pubDate>
      <description>$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a si</description>
    </item>
  </channel>
</rss>